The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
"I'm starting to feel like a human being, not a fat a anymore," he said, while humorously acknowledging that he was oblivious to the mechanisms of how the drug actually worked to cut down his weight
Continuous clinical oversight helps members stay on a GLP-1 when appropriate, while intensive coaching and personalized nutrition recommendations empower members to build habits needed to sustain nutrition and lifestyle changes
Hypersensitivity reactions, including anaphylaxis, anaphylactoid reactions, angioedema, rash, and urticaria, have been reported postmarketing with use of semaglutide